SOLIRIS (eculizumab): The first treatment specifically approved for PNH

For US Healthcare Professionals

PNH Registry

The PNH Registry

Developed to further the medical community's understanding and management of PNH

PNH RegistryThe PNH Registry is the first prospective, international, longitudinal research initiative and database on patients with PNH. The PNH Registry was created to

  • Enhance understanding of PNH to optimize patient outcomes
  • Encourage collaboration and scientific exchange
  • Generate data reports to enable evidence-based diagnostic and treatment decision-making

Sponsored by Alexion Pharmaceuticals and supported by an International Scientific Advisory Board, the PNH Registry aims to join together physicians and patients from around the world.

Enrolling your patients

All patients with PNH — either newly or previously diagnosed — are eligible for enrollment in the PNH Registry.

Enroll your patients in the PNH Registry today, and help further our understanding of PNH for both current and future generations.

Next: About SOLIRIS® (eculizumab)

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS; revaccinate according to current medication guidelines for vaccine use.

Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.